Week in Review: China's Waterstone Pharma Acquires Global Rights to Anti-Viral

China's Waterstone Pharma in-licensed global rights to a treatment for chronic viral infections (especially hepatitis C) from SCYNEXIS of the US; Shenzhen Hepalink Pharma will invest $22 million in a TPG life science VC fund; UniTao Pharma of China bought an about-to-idled Boehringer Ingelheim API plant in Virginia for an undisclosed sum; Bayer AG closed its $589 million acquisition of China's Dihon Pharma, an OTC/TCM healthcare company; cross-border partnerships in biologics will set a record in 2014, said Greg Scott, Founder of ChinaBio®, at the recent ChinaBio® Leadership Retreat in Changshu; Johnson & Johnson's new Asia Pacific Innovation Center in Shanghai has already signed six deals with Asia Pacific partners, four of them in China; Roche will invest $466 million to build a facility in Suzhou to manufacture diagnostic tests; Daewoong Pharma of Korea opened a laboratory in Liaoning to develop oral solutions and solid drugs for China; and STAAR Surgical of California received China marketing approval for its latest implantable eye lens. More details.... Stock Symbols: (SHE: 002399) (XETRA: BAYN) (NYSE: JNJ) (SIX: RO, ROG) (KRX: 069620) (NSDQ: STAA) Share this with colleagues: // //